Half-Year 2022 Financial and Clinical Trials Update slide image

Half-Year 2022 Financial and Clinical Trials Update

Roche Tiragolumab (anti-TIGIT, RG6058, MTIG7192A) Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT Indication Phase/study # of patients Design Locally advanced esophageal cancer (EC) Phase III SKYSCRAPER-07 N=750 ARM A: Tiragolumab plus Tecentriq ARM B: Tecentriq plus placebo ARM C: Placebo plus placebo " 1L esophageal cancer (EC) Phase III SKYSCRAPER-08 N=500 ARM A: Tiragolumab plus Tecentriq plus cisplatin and paclitaxel ARM B: Placebo plus placebo plus cisplatin and paclitaxel 1L recurrent/metastatic PD-L1 positive squamous cell head and neck carcinoma (SCCHN) Phase II SKYSCRAPER-09 N=120 ARM A: Tiragolumab plus Tecentriq ARM B: Tecentriq plus placebo ▪ Progression-free survival (A vs C) ◉ Overall survival and progression-free survival ■ Objective response rate Primary endpoint ■ Overall survival (A vs C, hierarchical, B vs C hierarchical) FPI Q3 2020 ■ FPI Q1 2021 Status CT Identifier NCT04543617 NSCLC-Non-small cell lung cancer; PD-L1-Programmed cell death-ligand 1 " FPI Q4 2020 Recruitment completed Q4 2021 NCT04540211 ■ Recruitment completed Q2 2022 NCT04665843 129 Oncology
View entire presentation